Daniel J Drucker Selected Research

Glucagon-Like Peptides (Enteroglucagon)

1/2020	Proglucagon-Derived Peptides, Glucose-Dependent Insulinotropic Polypeptide, and Dipeptidyl Peptidase-4-Mechanisms of Action in Adipose Tissue.
1/2020	Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation.
10/2017	Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion.
2/2012	Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disorders.
10/2005	Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
7/2002	Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel J Drucker Research Topics

Disease

60	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2002
38	Obesity 01/2022 - 05/2006
38	Body Weight (Weight, Body) 01/2022 - 03/2003
24	Insulin Resistance 01/2019 - 10/2003
22	Inflammation (Inflammations) 01/2021 - 05/2006
17	Weight Loss (Weight Reduction) 01/2021 - 11/2006
13	Hyperglycemia 11/2018 - 02/2003
10	Hypoglycemia (Reactive Hypoglycemia) 04/2019 - 10/2003
9	Weight Gain 01/2022 - 11/2006
9	Neoplasms (Cancer) 04/2019 - 07/2002
8	Myocardial Infarction 11/2021 - 04/2009
8	Glucose Intolerance 01/2018 - 02/2004
6	Atherosclerosis 11/2021 - 01/2013
6	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 11/2007
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 07/2009
5	Ischemia 10/2017 - 05/2008
5	Hyperplasia 04/2013 - 04/2010
4	Fibrosis (Cirrhosis) 01/2020 - 01/2013
4	Diabetes Mellitus 08/2017 - 01/2002
3	Nausea 01/2021 - 01/2002
3	Albuminuria 01/2020 - 03/2014
3	Hypertension (High Blood Pressure) 01/2020 - 10/2016
3	Short Bowel Syndrome 04/2019 - 01/2014
3	Pancreatitis 01/2018 - 09/2009
3	medullary Thyroid cancer 01/2018 - 07/2011
3	Infarction (Infarctions) 02/2015 - 04/2009
3	Anorexia 04/2013 - 01/2005
2	Stroke (Strokes) 11/2021 - 01/2018
2	Vomiting 01/2021 - 01/2002
2	Metabolic Diseases (Metabolic Disease) 01/2021 - 01/2017
2	Intestinal Failure 01/2020 - 01/2020
2	Cardiomegaly (Heart Hypertrophy) 01/2020 - 03/2016
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018 - 05/2006
2	Vascular System Injuries 01/2018 - 12/2016
2	Heart Diseases (Heart Disease) 11/2017 - 07/2009
2	Hypertrophy 02/2015 - 01/2013
2	Necrosis 01/2013 - 01/2003
2	Colitis 06/2012 - 02/2002
2	Enteritis 03/2012 - 02/2002
2	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 02/2012 - 12/2004

Drug/Important Bio-Agent (IBA)

62	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2002
61	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 01/2002
32	Glucagon-Like Peptide-1 ReceptorIBA 11/2021 - 09/2005
25	Glucagon (Glukagon)FDA Link 01/2022 - 10/2003
25	IncretinsIBA 01/2019 - 01/2002
18	Insulin (Novolin)FDA Link 01/2022 - 10/2003
15	Liraglutide FDA Link 01/2022 - 11/2006
15	Peptides (Polypeptides)IBA 01/2021 - 01/2002
13	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2018 - 01/2002
12	Hormones (Hormone)IBA 01/2021 - 07/2002
11	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2002
11	Exenatide (Byetta)FDA Link 03/2015 - 01/2003
8	Glucagon Receptors (Glucagon Receptor)IBA 11/2018 - 10/2005
8	Blood Glucose (Blood Sugar)IBA 04/2013 - 01/2002
7	Sitagliptin Phosphate (Januvia)FDA Link 01/2020 - 11/2006
6	semaglutideIBA 01/2022 - 08/2017
6	gastric inhibitory polypeptide receptorIBA 01/2022 - 01/2012
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2008
6	LipidsIBA 01/2020 - 06/2010
6	Glucagon-Like Peptides (Enteroglucagon)IBA 01/2020 - 07/2002
5	LeptinIBA 01/2021 - 01/2008
5	Pharmaceutical PreparationsIBA 01/2021 - 02/2002
5	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 01/2002
5	EnzymesIBA 01/2020 - 05/2007
5	Biological ProductsIBA 10/2019 - 01/2003
5	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 10/2017 - 01/2002
4	Triglycerides (Triacylglycerol)IBA 01/2021 - 04/2008
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2018
4	Messenger RNA (mRNA)IBA 10/2019 - 10/2003
4	Proglucagon (Glucagon Precursors)IBA 04/2019 - 07/2002
4	Streptozocin (Streptozotocin)FDA Link 11/2015 - 11/2008
3	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2020 - 02/2008
3	Therapeutic UsesIBA 10/2019 - 02/2002
3	CytokinesIBA 10/2019 - 01/2003
3	fibroblast growth factor 21IBA 01/2018 - 01/2016
3	Hypoglycemic Agents (Hypoglycemics)IBA 01/2018 - 09/2009
3	Dextran SulfateIBA 06/2012 - 02/2002
3	Glucagon-Like Peptide-2 ReceptorIBA 09/2010 - 10/2005
2	Interleukin-6 (Interleukin 6)IBA 10/2019 - 10/2011
2	teduglutideIBA 04/2019 - 02/2015
2	SugarsIBA 01/2019 - 04/2013
2	Lipoproteins (Lipoprotein)IBA 08/2017 - 09/2009
2	Peptide Hormones (Polypeptide Hormones)IBA 12/2016 - 07/2013
2	CholesterolIBA 10/2016 - 01/2015
2	SodiumIBA 10/2016 - 01/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2016 - 08/2014
2	salicylhydroxamic acid (SHAM)IBA 03/2014 - 02/2003
2	GastrinsIBA 07/2013 - 10/2003
2	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 07/2013 - 01/2002
2	NF-kappa B (NF-kB)IBA 01/2013 - 05/2006
2	ThiazolidinedionesIBA 02/2011 - 01/2006
2	glycogen synthase kinase 3 alphaIBA 10/2008 - 10/2007
2	Glycogen Synthase Kinase 3IBA 10/2008 - 10/2007

Therapy/Procedure

28	Therapeutics 01/2022 - 01/2002
6	Glycemic Control 01/2021 - 06/2010
5	Bariatric Surgery 01/2022 - 07/2013
3	Drug Therapy (Chemotherapy) 01/2022 - 02/2002
3	Injections 01/2021 - 11/2006
2	Ligation 02/2015 - 04/2010
2	Parenteral Nutrition 02/2015 - 01/2014